DTIL Strangle Strategy
DTIL (Precision BioSciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma.
DTIL (Precision BioSciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $93.5M, a beta of 1.28 versus the broader market, a 52-week range of 3.53-8.82, average daily share volume of 330K, a public-listing history dating back to 2019, approximately 108 full-time employees. These structural characteristics shape how DTIL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.28 places DTIL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on DTIL?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current DTIL snapshot
As of June 30, 2026, spot at $7.90, ATM IV 109.20%, IV rank 21.02%, expected move 31.31%. The strangle on DTIL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on DTIL specifically: DTIL IV at 109.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a DTIL strangle, with a market-implied 1-standard-deviation move of approximately 31.31% (roughly $2.47 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DTIL expiries trade a higher absolute premium for lower per-day decay. Position sizing on DTIL should anchor to the underlying notional of $7.90 per share and to the trader's directional view on DTIL stock.
DTIL strangle setup
The DTIL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DTIL near $7.90, the first option leg uses a $8.30 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DTIL chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DTIL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $8.30 | N/A |
| Buy 1 | Put | $7.51 | N/A |
DTIL strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
DTIL strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on DTIL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on DTIL
Strangles on DTIL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DTIL chain.
DTIL thesis for this strangle
The market-implied 1-standard-deviation range for DTIL extends from approximately $5.43 on the downside to $10.37 on the upside. A DTIL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current DTIL IV rank near 21.02% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DTIL at 109.20%. As a Healthcare name, DTIL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DTIL-specific events.
DTIL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DTIL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DTIL alongside the broader basket even when DTIL-specific fundamentals are unchanged. Always rebuild the position from current DTIL chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on DTIL?
- A strangle on DTIL is the strangle strategy applied to DTIL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With DTIL stock trading near $7.90, the strikes shown on this page are snapped to the nearest listed DTIL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DTIL strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the DTIL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 109.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DTIL strangle?
- The breakeven for the DTIL strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DTIL market-implied 1-standard-deviation expected move is approximately 31.31%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on DTIL?
- Strangles on DTIL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the DTIL chain.
- How does current DTIL implied volatility affect this strangle?
- DTIL ATM IV is at 109.20% with IV rank near 21.02%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.